Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Ann Intern Med ; 174(12): 1700-1709, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34543588

RESUMO

BACKGROUND: Fully assessing the mortality burden of the COVID-19 pandemic requires measuring years of life lost (YLLs) and accounting for quality-of-life differences. OBJECTIVE: To measure YLLs and quality-adjusted life-years (QALYs) lost from the COVID-19 pandemic, by age, sex, race/ethnicity, and comorbidity. DESIGN: State-transition microsimulation model. DATA SOURCES: Health and Retirement Study, Panel Study of Income Dynamics, data on excess deaths from the Centers for Disease Control and Prevention, and nursing home death counts from the Centers for Medicare & Medicaid Services. TARGET POPULATION: U.S. population aged 25 years and older. TIME HORIZON: Lifetime. PERSPECTIVE: Individual. INTERVENTION: COVID-19 pandemic through 13 March 2021. OUTCOME MEASURES: YLLs and QALYs lost per 10 000 persons in the population. The estimates account for the age, sex, and race/ethnicity of decedents, along with obesity, smoking behavior, lung disease, heart disease, diabetes, cancer, stroke, hypertension, dementia, and nursing home residence. RESULTS OF BASE-CASE ANALYSIS: The COVID-19 pandemic resulted in 6.62 million QALYs lost (9.08 million YLLs) through 13 March 2021, with 3.6 million (54%) lost by those aged 25 to 64 years. The greatest toll was on Black and Hispanic communities, especially among men aged 65 years or older, who lost 1138 and 1371 QALYs, respectively, per 10 000 persons. Absent the pandemic, 38% of decedents would have had average or above-average life expectancies for their subgroup defined by age, sex, and race/ethnicity. RESULTS OF SENSITIVITY ANALYSIS: Accounting for uncertainty in risk factors for death from COVID-19 yielded similar results. LIMITATION: Estimates may vary depending on assumptions about mortality and quality-of-life projections. CONCLUSION: Beyond excess deaths alone, the COVID-19 pandemic imposed a greater life expectancy burden on persons aged 25 to 64 years, including those with average or above-average life expectancies, and a disproportionate burden on Black and Hispanic communities. PRIMARY FUNDING SOURCE: National Institute on Aging.


Assuntos
COVID-19/mortalidade , Pandemias , Adulto , Distribuição por Idade , Idoso , COVID-19/etnologia , COVID-19/prevenção & controle , Vacinas contra COVID-19 , Comorbidade , Efeitos Psicossociais da Doença , Modelos Epidemiológicos , Minorias Étnicas e Raciais/estatística & dados numéricos , Disparidades nos Níveis de Saúde , Humanos , Expectativa de Vida , Pessoa de Meia-Idade , Anos de Vida Ajustados por Qualidade de Vida , Fatores de Risco , SARS-CoV-2 , Distribuição por Sexo , Estados Unidos/epidemiologia
2.
Environ Energy Policy Econ ; 2: 157-189, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33554211

RESUMO

Policies aimed at reducing the harmful effects of air pollution exposure typically focus on areas with high levels of pollution. However, if a population's vulnerability to air pollution is imperfectly correlated with current pollution levels, then this approach to air quality regulation may not efficiently target pollution reduction efforts. We examine the geographic and socioeconomic determinants of vulnerability to dying from acute exposure to fine particulate matter (PM2.5) pollution. We find that there is substantial local and regional variability in the share of individuals who are vulnerable to pollution both at the county and ZIP code level. Vulnerability tends to be negatively related to health and socioeconomic status. Surprisingly, we find that vulnerability is also negatively related to an area's average PM2.5 pollution level, suggesting that basing air quality regulation only on current pollution levels may fail to effectively target regions with the most to gain by reducing exposure.

3.
JAMA Intern Med ; 181(2): 292-293, 2021 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-33346803
5.
JAMA Intern Med ; 180(7): 952-960, 2020 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-32453346

RESUMO

Importance: Many employers use workplace wellness programs to improve employee health and reduce medical costs, but randomized evaluations of their efficacy are rare. Objective: To evaluate the effect of a comprehensive workplace wellness program on employee health, health beliefs, and medical use after 12 and 24 months. Design, Setting, and Participants: This randomized clinical trial of 4834 employees of the University of Illinois at Urbana-Champaign was conducted from August 9, 2016, to April 26, 2018. Members of the treatment group (n = 3300) received incentives to participate in the workplace wellness program. Members of the control group (n = 1534) did not participate in the wellness program. Statistical analysis was performed on April 9, 2020. Interventions: The 2-year workplace wellness program included financial incentives and paid time off for annual on-site biometric screenings, annual health risk assessments, and ongoing wellness activities (eg, physical activity, smoking cessation, and disease management). Main Outcomes and Measures: Measures taken at 12 and 24 months included clinician-collected biometrics (16 outcomes), administrative claims related to medical diagnoses (diabetes, hypertension, and hyperlipidemia) and medical use (office visits, inpatient visits, and emergency department visits), and self-reported health behaviors and health beliefs (14 outcomes). Results: Among the 4834 participants (2770 women; mean [SD] age, 43.9 [11.3] years), no significant effects of the program on biometrics, medical diagnoses, or medical use were seen after 12 or 24 months. A significantly higher proportion of employees in the treatment group than in the control group reported having a primary care physician after 24 months (1106 of 1200 [92.2%] vs 477 of 554 [86.1%]; adjusted P = .002). The intervention significantly improved a set of employee health beliefs on average: participant beliefs about their chance of having a body mass index greater than 30, high cholesterol, high blood pressure, and impaired glucose level jointly decreased by 0.07 SDs (95% CI, -0.12 to -0.01 SDs; P = .02); however, effects on individual belief measures were not significant. Conclusions and Relevance: This randomized clinical trial showed that a comprehensive workplace wellness program had no significant effects on measured physical health outcomes, rates of medical diagnoses, or the use of health care services after 24 months, but it increased the proportion of employees reporting that they have a primary care physician and improved employee beliefs about their own health. Trial Registration: American Economic Association Randomized Controlled Trial Registry number: AEARCTR-0001368.


Assuntos
Exercício Físico/fisiologia , Comportamentos Relacionados com a Saúde , Promoção da Saúde , Serviços de Saúde do Trabalhador/economia , Saúde Ocupacional , Avaliação de Programas e Projetos de Saúde , Medição de Risco/métodos , Adulto , Índice de Massa Corporal , Feminino , Gastos em Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Motivação , Estudos Retrospectivos , Autorrelato , Local de Trabalho/estatística & dados numéricos
6.
Am J Health Promot ; 34(4): 445, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-32088971
7.
Q J Econ ; 134(4): 1747-1791, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31564754

RESUMO

Workplace wellness programs cover over 50 million U.S. workers and are intended to reduce medical spending, increase productivity, and improve well-being. Yet limited evidence exists to support these claims. We designed and implemented a comprehensive workplace wellness program for a large employer and randomly assigned program eligibility and financial incentives at the individual level for nearly 5,000 employees. We find strong patterns of selection: during the year prior to the intervention, program participants had lower medical expenditures and healthier behaviors than nonparticipants. The program persistently increased health screening rates, but we do not find significant causal effects of treatment on total medical expenditures, other health behaviors, employee productivity, or self-reported health status after more than two years. Our 95% confidence intervals rule out 84% of previous estimates on medical spending and absenteeism.

8.
Am Econ Rev ; 109(12): 4178-4219, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-32189719

RESUMO

We estimate the causal effects of acute fine particulate matter exposure on mortality, health care use, and medical costs among the US elderly using Medicare data. We instrument for air pollution using changes in local wind direction and develop a new approach that uses machine learning to estimate the life-years lost due to pollution exposure. Finally, we characterize treatment effect heterogeneity using both life expectancy and generic machine learning inference. Both approaches find that mortality effects are concentrated in about 25 percent of the elderly population.

9.
J Health Econ ; 53: 17-37, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28273626

RESUMO

We investigate the implementation of Medicare Part D and estimate that this prescription drug benefit program reduced elderly mortality by 2.2% annually. This was driven primarily by a reduction in cardiovascular mortality, the leading cause of death for the elderly. There was no effect on deaths due to cancer, a condition whose drug treatments are covered under Medicare Part B. We validate these results by demonstrating that the changes in drug utilization following the implementation of Medicare Part D match the mortality patterns we observe. We calculate that the value of the mortality reduction is equal to $5 billion per year.


Assuntos
Doenças Cardiovasculares/mortalidade , Causas de Morte/tendências , Medicare Part D/economia , Medicamentos sob Prescrição/economia , Idoso , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/economia , Humanos , Medicare Part D/tendências , Medicamentos sob Prescrição/uso terapêutico , Estados Unidos/epidemiologia
10.
PLoS One ; 9(3): e90290, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24603414

RESUMO

BACKGROUND: Countries face conflicting incentives to report infectious disease outbreaks. Reports of outbreaks can prompt other countries to impose trade and travel restrictions, which has the potential to discourage reporting. However, reports can also bring medical assistance to contain the outbreak, including access to vaccines. METHODS: We compiled data on reports of meningococcal meningitis to the World Health Organization (WHO) from 54 African countries between 1966 and 2002, a period is marked by two events: first, a large outbreak reported from many countries in 1987 associated with the Hajj that resulted in more stringent requirements for meningitis vaccination among pilgrims; and second, another large outbreak in Sub-Saharan Africa in 1996 that led to a new international mechanism to supply vaccines to countries reporting a meningitis outbreak. We used fixed-effects regression modeling to statistically estimate the effect of external forcing events on the number of countries reporting cases of meningitis to WHO. FINDINGS: We find that the Hajj vaccination requirements started in 1988 were associated with reduced reporting, especially among countries with relatively fewer cases reported between 1966 and 1979. After the vaccine provision mechanism was in place in 1996, reporting among countries that had previously not reported meningitis outbreaks increased. INTERPRETATION: These results indicate that countries may respond to changing incentives to report outbreaks when they can do so. In the long term, these incentives are likely to be more important than surveillance assistance in prompt reporting of outbreaks.


Assuntos
Surtos de Doenças/estatística & dados numéricos , Saúde Global/estatística & dados numéricos , Disseminação de Informação , Meningite Meningocócica/epidemiologia , África/epidemiologia , Saúde Global/tendências , Humanos , Cooperação Internacional , Meningite Meningocócica/imunologia , Meningite Meningocócica/prevenção & controle , Vacinas Meningocócicas/administração & dosagem , Vacinas Meningocócicas/imunologia , Vigilância da População , Vacinação , Organização Mundial da Saúde
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA